234 related articles for article (PubMed ID: 36813854)
1. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
Baek ML; Lee J; Pendleton KE; Berner MJ; Goff EB; Tan L; Martinez SA; Mahmud I; Wang T; Meyer MD; Lim B; Barrish JP; Porter W; Lorenzi PL; Echeverria GV
Oncogene; 2023 Mar; 42(14):1117-1131. PubMed ID: 36813854
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
Winter M; Nait Eldjoudi A; Guette C; Hondermarck H; Bourette RP; Fovez Q; Laine W; Ghesquiere B; Adriaenssens E; Kluza J; Le Bourhis X
Neoplasia; 2023 Dec; 46():100949. PubMed ID: 37956532
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
6. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW; Yuca E; Scott SS; Zhao M; Paez Arango N; Cruz Pico CX; Saridogan T; Shariati M; Class CA; Bristow CA; Vellano CP; Zheng X; Gonzalez-Angulo AM; Su X; Tapia C; Chen K; Akcakanat A; Lim B; Tripathy D; Yap TA; Francesco MED; Draetta GF; Jones P; Heffernan TP; Marszalek JR; Meric-Bernstam F
Cancer Res; 2021 Nov; 81(21):5572-5581. PubMed ID: 34518211
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
8. FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway.
Urra FA; Muñoz F; Córdova-Delgado M; Ramírez MP; Peña-Ahumada B; Rios M; Cruz P; Ahumada-Castro U; Bustos G; Silva-Pavez E; Pulgar R; Morales D; Varela D; Millas-Vargas JP; Retamal E; Ramírez-Rodríguez O; Pessoa-Mahana H; Pavani M; Ferreira J; Cárdenas C; Araya-Maturana R
Sci Rep; 2018 Sep; 8(1):13190. PubMed ID: 30181620
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
10. Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.
Humphries BA; Cutter AC; Buschhaus JM; Chen YC; Qyli T; Palagama DSW; Eckley S; Robison TH; Bevoor A; Chiang B; Haley HR; Sahoo S; Spinosa PC; Neale DB; Boppisetti J; Sahoo D; Ghosh P; Lahann J; Ross BD; Yoon E; Luker KE; Luker GD
Breast Cancer Res; 2020 Jun; 22(1):60. PubMed ID: 32503622
[TBL] [Abstract][Full Text] [Related]
11. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract][Full Text] [Related]
12. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
[TBL] [Abstract][Full Text] [Related]
13. A gold-based inhibitor of oxidative phosphorylation is effective against triple negative breast cancer.
Mertens RT; Kim JH; Ofori S; Olelewe C; Kamitsuka PJ; Kwakye GF; Awuah SG
Biomed Pharmacother; 2024 Jan; 170():116010. PubMed ID: 38128183
[TBL] [Abstract][Full Text] [Related]
14. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.
Echeverria GV; Ge Z; Seth S; Zhang X; Jeter-Jones S; Zhou X; Cai S; Tu Y; McCoy A; Peoples M; Sun Y; Qiu H; Chang Q; Bristow C; Carugo A; Shao J; Ma X; Harris A; Mundi P; Lau R; Ramamoorthy V; Wu Y; Alvarez MJ; Califano A; Moulder SL; Symmans WF; Marszalek JR; Heffernan TP; Chang JT; Piwnica-Worms H
Sci Transl Med; 2019 Apr; 11(488):. PubMed ID: 30996079
[TBL] [Abstract][Full Text] [Related]
15. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine.
Hu J; Zhang Y; Jiang X; Zhang H; Gao Z; Li Y; Fu R; Li L; Li J; Cui H; Gao N
J Exp Clin Cancer Res; 2019 May; 38(1):225. PubMed ID: 31138329
[TBL] [Abstract][Full Text] [Related]
16. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth.
Zamberlan M; Boeckx A; Muller F; Vinelli F; Ek O; Vianello C; Coart E; Shibata K; Christian A; Grespi F; Giacomello M; Struman I; Scorrano L; Herkenne S
J Exp Clin Cancer Res; 2022 Mar; 41(1):95. PubMed ID: 35279198
[TBL] [Abstract][Full Text] [Related]
18. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
[No Abstract] [Full Text] [Related]
19. MicroRNA-Mediated Mitochondrial Dysfunction Is Involved in the Anti-triple-Negative Breast Cancer Cell Activity of Phytosesquiterpene Lactones.
Cheng YT; Nakagawa-Goto K; Lee KH; Shyur LF
Antioxid Redox Signal; 2023 Jan; 38(1-3):198-214. PubMed ID: 35850524
[No Abstract] [Full Text] [Related]
20. Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells.
Chen L; Zhang J; Lyu Z; Chen Y; Ji X; Cao H; Jin M; Zhu J; Yang J; Ling R; Xing J; Ren T; Lyu Y
Cell Death Dis; 2018 Oct; 9(11):1050. PubMed ID: 30323195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
